Sequential therapy with bevacizumab and epidermal growth factor receptor-directed agents for metastatic colorectal carcinoma: A retrospective, registry-based analysis

<p>Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies</p>

“…Alternatively, a small retrospective analysis that investigated the survival of KRAS WT patients who were sequentially treated with cetuximab and bevacizumab reported that patients receiving bevacizumab first had similar survival outcomes compared to patients receiving cetuximab first (PFS: 13 vs 10 months, P =0.798; OS: 44 vs 39 months, P =0.862) 29. Burge et al analyzed a multicenter registry and found that initial bevacizumab use did not impact the efficacy of EGFR antibodies in subsequent therapy as PFS and OS from anti-EGFR mAb commencement were not significantly different from prior bevacizumab use,32 which is similar to other reports 30,31. In addition, a longer gap between bevacizumab and anti-EGFR mAb (>6 months) was linked to a longer median PFS in right-sided tumors, while left-sided tumors had no difference, which may reflect a distinct subgroup with a superior prognosis in right-sided tumors 32…”

Previous Bevacizumab and Efficacy of Later Anti–Epidermal Growth Factor Receptor Antibodies in Metastatic Colorectal Cancer: Results From a Large International Registry

“…Our findings are consistent with those of other registry analyses which have shown no impact of prior bevacizumab on later EGFRI efficacy. 15,16 In contrast, prospective trials investigating the optimal second line biologic, after first line bevacizumab, have produced conflicting results. The PRODIGE-18 study randomised 133 KRAS exon 2 wild type patients who had progressed after first line chemotherapy plus bevacizumab to the alternate chemotherapy backbone plus either cetuximab or bevacizumab.…”